Scholar Rock (SRRK)

AI Score

Unlock

32.50

2.44 (8.12%)

At close: Apr 02, 2025, 3:59 PM

34.65

6.62%

After-hours: Apr 02, 2025, 07:11 PM EDT

Dividends

No dividend history available for Scholar Rock.

Pro Subscription

Upgrade now for unlimited access to all data and tools.

Dividend Definition

Dividends are payments made by a company to its shareholders, typically derived from its profits. They represent a portion of earnings distributed to investors as a reward for holding shares. Dividends do not account for retained earnings or reinvestments and are therefore different from a company's total profits.

Related Stocks

Company	Dividend Yield

Dividend Rankings

SRRK News

1 week ago · FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy - businesswire.com
2 weeks ago · Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment - benzinga.com
2 weeks ago · Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference - businesswire.com
2 weeks ago · Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - businesswire.com
1 month ago · Scholar Rock Holding Corporation (SRRK) Q4 2024 Earnings Call Transcript - seekingalpha.com
1 month ago · Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - businesswire.com
2 months ago · Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data - seekingalpha.com
2 months ago · Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) - businesswire.com
2 months ago · Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth - benzinga.com